Motac Neuroscience Ltd is a leading provider of highly specialized preclinical research services for the pharmaceutical and biotechnology industries, focusing on the discovery and development of novel therapies for neurological and psychiatric disorders. With extensive expertise and world-class research capabilities in neurodegenerative conditions, particularly Parkinson’s disease, other movement disorders, and cognitive disorders, Motac specializes in preclinical proof-of-concept and efficacy studies. The company distinguishes itself through unparalleled access to the best available models of these conditions, underpinned by first-class scientific understanding, with a strong emphasis on quality and timeliness.
With a history of widely published personnel in high-quality, peer-reviewed, scientific journals and a significant intellectual property portfolio, including new chemical entities and novel therapeutic targets for the treatment of movement disorders, Motac Neuroscience Ltd is strategically positioned for growth through alliances and partnerships. Since its founding in 1999, the company has been instrumental in elucidating the brain mechanisms that mediate disorders of movement, leading to the introduction of new treatments. Its unique approach and strong foundation set it apart in the Health Care, Pharmaceutical, and Marketing industries, making it an attractive prospect for investors seeking opportunities in innovative healthcare solutions.
There is no investment information
No recent news or press coverage available for Motac Neuroscience Ltd.
We care about your data, and we'd love to use cookies make your experience better.
